Riociguat Patent Expiration
Riociguat is used for treating chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) to improve exercise capacity and WHO functional class, and delay clinical worsening. It was first introduced by Bayer Healthcare Pharmaceuticals Inc
Riociguat Patents
Given below is the list of patents protecting Riociguat, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Adempas | US10662188 | Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate | Feb 18, 2034 | Bayer Hlthcare |
| Adempas | US11203593 | Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate | Feb 18, 2034 | Bayer Hlthcare |
| Adempas | US12503469 | Forms Of Methyl {4,6-Diamino-2-[1-(2-Fluorobenzyl)-1H-Pyrazolo[3-4-B]Pyridino-3-Yl]Pyrimidino-5-Yl} Methyl Carbamate | Feb 18, 2034 | Bayer Hlthcare |
| Adempas | US7173037 | Carbamate-substituted pyrazolopyridines | Dec 04, 2026 | Bayer Hlthcare |
| Adempas | US6743798 | Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
Jul 16, 2019
(Expired) | Bayer Hlthcare |
Riociguat's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Riociguat:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary Angioplasty | Assistance Publique - Hôpitaux de Paris | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction | Bayer | NA |
TERMINATED
(Aug 1, 2026)
| PHASE2 |
| Riociguat in Children With Pulmonary Arterial Hypertension (PAH) | Bayer | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |